OPRX · OptimizeRx Corporation

Summary

OptimizeRx Corporation entered into Amendment No. 4 to its Financing Agreement extending maturity to October 11, 2029 and permitting a $10 million share repurchase, reported record Q4 and full year 2025 financial results with revenue of $109.4 million and updated 2026 guidance to $109-$114 million revenue and $21-$25 million adjusted EBITDA.

Key takeaways

• Event Type: Earnings Release, Financing Amendment, Share Repurchase Authorization (Items: 1.01, 2.02)